https://www.beacontx.com/ A Syncona portfolio company Wed, 10 Sep 2025 20:30:50 +0000 en-GB hourly 1 https://wordpress.org/?v=6.8.3 https://www.beacontx.com/news-and-events/beacon-therapeutics-to-participate-in-the-2025-bank-of-america-healthcare/ Wed, 10 Sep 2025 12:00:00 +0000 https://www.beacontx.com/?p=7437 The post Beacon Therapeutics to Participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics to Participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-announces-positive-interim-9-month-results-fromdawn-trial-and-36-month-phase-2-skyline-trial-data-for-laru-zova-in-patients/ Thu, 04 Sep 2025 12:00:00 +0000 https://www.beacontx.com/?p=7386 The post Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025 appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025 appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-announces-euretina-2025-presentations-on-9-month-phase-2-dawn-and-36-month-phase-2-skyline-trial-data-for-laru-zova-in-patients-with-x-linked-retinitis-pigmentosa-xlrp/ Thu, 21 Aug 2025 12:00:00 +0000 https://www.beacontx.com/?p=7301 The post Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-completes-enrollment-in-registrational-phase-2-3-vista-trial-of-laru-zova-for-patients-with-xlrp/ Tue, 08 Jul 2025 12:00:00 +0000 https://www.beacontx.com/?p=7065 The post Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-strengthens-leadership-team-with-the-appointment-of/ Mon, 09 Jun 2025 12:00:00 +0000 https://www.beacontx.com/?p=6887 The post Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-announces-positive-phase-2-interim-6-month-data-from-dawn-trial-of-laru-zova-in-patients-with-x-linked-retinitis-pigmentosa-xlrp-at-arvo-2025/ Tue, 06 May 2025 16:00:00 +0000 https://www.beacontx.com/?p=6662 The post Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025 appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025 appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-announces-arvo-2025-presentation-on-preliminary-6-month-data-from-its-phase-2-dawn-trial-of-laru-zova-in-patients-with-x-linked-retinitis-pigmentosa-xlrp/ Thu, 24 Apr 2025 07:00:00 +0000 https://www.beacontx.com/?p=6533 The post Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data from its Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Announces ARVO 2025 Presentation on Preliminary 6-Month Data from its Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-rmat/ Tue, 28 Jan 2025 13:00:00 +0000 https://www.beacontx.com/?p=5895 The post  Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT)  appeared first on Beacon Therapeutics.

]]> The post  Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT)  appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-laru-zova-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa-xlrp/ Fri, 06 Dec 2024 12:00:00 +0000 https://www.beacontx.com/?p=5545 The post Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) appeared first on Beacon Therapeutics.

]]> https://www.beacontx.com/news-and-events/beacon-therapeutics-announces-positive-24-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa/ Tue, 15 Oct 2024 14:00:00 +0000 https://www.beacontx.com/?p=5052 The post Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa appeared first on Beacon Therapeutics.

]]> The post Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa appeared first on Beacon Therapeutics.

]]>